SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001725160-23-000170
Filing Date
2023-10-04
Accepted
2023-10-04 20:26:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3581
  Complete submission text file 0001725160-23-000170.txt   5118
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Subject) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39263 | Film No.: 231309561
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Bunker Kevin D. (Reporting) CIK: 0001807484 (see all company filings)

Type: 144